Literature DB >> 20353976

Antiphospholipid antibodies and the protein C pathway.

R T Urbanus1, B de Laat.   

Abstract

Haemostasis is a delicate balance between procoagulant and anticoagulant processes. In the human body usually anticoagulant mechanisms prevail over procoagulant mechanisms, thereby preventing a prothrombotic state. The antiphospholipid syndrome is an example in which this balance is shifted to a more prothrombotic state due to the presence of antiphospholipid antibodies. One of the most extensively proposed pathogenic mechanisms within the antiphospholipid syndrome is the inhibition of protein C by antiphospholipid antibodies. Antiphospholipid antibodies have been described to have different actions on the protein C pathway, for example decreasing protein C and/or S plasma levels, inducing increased resistance against activated protein C and lowering thrombin levels (resulting in an impaired protein C activation). This review briefly discusses the actions of protein C in human body but mainly focuses on the effects of antiphospholipid antibodies on the protein C pathway that have been described in literature.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20353976     DOI: 10.1177/0961203309360841

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  15 in total

Review 1.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

Review 2.  Diagnosis and management of the antiphospholipid syndrome.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Blood Rev       Date:  2017-07-30       Impact factor: 8.250

3.  Anti-β2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway.

Authors:  Venkaiah Betapudi; George Lominadze; Linda Hsi; Belinda Willard; Meifang Wu; Keith R McCrae
Journal:  Blood       Date:  2013-08-16       Impact factor: 22.113

4.  Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations.

Authors:  Shruti Chaturvedi; Erin Cockrell; Ricardo Espinola; Linda Hsi; Stacey Fulton; Mohammad Khan; Liang Li; Fabio Fonseca; Suman Kundu; Keith R McCrae
Journal:  Thromb Res       Date:  2014-11-15       Impact factor: 3.944

5.  Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin.

Authors:  Romy M W Kremers; Stéphane Zuily; Hilde Kelchtermans; Tessa C Peters; Saartje Bloemen; Véronique Regnault; H Coenraad Hemker; Philip G de Groot; Denis Wahl; Bas de Laat
Journal:  Blood Adv       Date:  2018-06-12

Review 6.  Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases.

Authors:  Pier Luigi Meroni; Martina Biggioggero; Silvia S Pierangeli; Joanna Sheldon; Ingrid Zegers; Maria Orietta Borghi
Journal:  Nat Rev Rheumatol       Date:  2013-11-26       Impact factor: 20.543

7.  Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis.

Authors:  Mathivanan Chinnaraj; William Planer; Vittorio Pengo; Nicola Pozzi
Journal:  Blood Adv       Date:  2019-06-11

Review 8.  Autoantibodies directed against domain I of beta2-glycoprotein I.

Authors:  Bas de Laat; Philip G de Groot
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

9.  Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS.

Authors:  Shruti Chaturvedi; Evan M Braunstein; Xuan Yuan; Jia Yu; Alice Alexander; Hang Chen; Eleni Gavriilaki; Ravi Alluri; Michael B Streiff; Michelle Petri; Mark A Crowther; Keith R McCrae; Robert A Brodsky
Journal:  Blood       Date:  2020-01-23       Impact factor: 25.476

10.  Antiphospholipid-related chorea.

Authors:  Silvio Peluso; Antonella Antenora; Anna De Rosa; Alessandro Roca; Gennaro Maddaluno; Vincenzo Brescia Morra; Giuseppe De Michele
Journal:  Front Neurol       Date:  2012-10-22       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.